Amgen, Teva Settle Patent Suit Over Neopogen Generic

Law360, Los Angeles (July 15, 2011, 10:04 PM EDT) -- A Pennsylvania federal judge on Friday approved a settlement between generics maker Teva Pharmaceuticals USA Inc. and Amgen Inc. that squashes Teva's hopes of marketing a copycat version of the blood drug Neopogen until 2013.

U.S. District Judge Stewart Dalzell's order held that Amgen's patents covering the use of human granulocyte colony-stimulating factor were valid and enforceable. Further, Teva is banned from marketing or selling its Neopogen generic until November 2013, according to the judge's decision.

The terms of the settlement, which were agreed upon earlier...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.